Views
3 years ago

220-Dictionary of Pharmaceutical Medicine, 2nd Edition-Gerhard Nahler Annette Mollet-3211898352-S

220-Dictionary of Pharmaceutical Medicine, 2nd Edition-Gerhard Nahler Annette Mollet-3211898352-S

220-Dictionary of Pharmaceutical Medicine, 2nd Edition-Gerhard Nahler Annette

  • Page 3 and 4: Gerhard NahlerDictionary ofPharmace
  • Page 5 and 6: ForewordIn the beginning was the wo
  • Page 7 and 8: Foreword of the 1st editionThe evol
  • Page 9 and 10: IXPreface of the 1st editionFinally
  • Page 11 and 12: 1abbreviated new drug application A
  • Page 13 and 14: 3actual-treated analysis syn. as-tr
  • Page 15 and 16: 5of a sign or symptom which is easi
  • Page 17 and 18: 7allele frequency Often called gene
  • Page 19: 9anecdotal study → see observatio
  • Page 22 and 23: 12audaudit trail → see data trail
  • Page 24 and 25: 14bento calculate the posterior odd
  • Page 26 and 27: 16biolent; FDA: “bioequivalent dr
  • Page 28 and 29: 18bloblock size Size of consecutive
  • Page 30 and 31: 20caccachexia def. unintended and p
  • Page 32 and 33: 22cascer patients); the method for
  • Page 34 and 35: 24cemCE marking (of a medical devic
  • Page 36 and 37: 26chrtain DNA and proteins; genes a
  • Page 38 and 39: 28cleclerical error syn. key-punch
  • Page 40 and 41: 30clijournals: Writing and editing
  • Page 42 and 43: 32coithis treatment (e.g. to follow
  • Page 44 and 45: 34comreporting”; → see also see
  • Page 46 and 47: 36connal data. It should be possibl
  • Page 48 and 49: 38conof exposure-outcome associatio
  • Page 50 and 51: 40coopolymer matrix), wax matrices,
  • Page 52 and 53:

    42cosare increasingly used to facil

  • Page 54 and 55:

    44cumcumulative incidence Number of

  • Page 56 and 57:

    46datdata dredging Multiple, exhaus

  • Page 58 and 59:

    48datto confirm that the correct pr

  • Page 60 and 61:

    50devcomparison, e.g. two group par

  • Page 62 and 63:

    52diadiagnostic A product used for

  • Page 64 and 65:

    54disdisqualification rate → see

  • Page 66 and 67:

    56drudrug FDA: (1) substance recogn

  • Page 68 and 69:

    58druTable 1Determining the Probabi

  • Page 70 and 71:

    60ecbEC birth date First date on wh

  • Page 72 and 73:

    62effensures and declares that the

  • Page 74 and 75:

    64eleelectronic signature OECD: “

  • Page 76 and 77:

    66enzinformation about the physical

  • Page 78 and 79:

    68ethofficial action indicated; OAI

  • Page 80 and 81:

    70excglidants (improving powder flo

  • Page 82 and 83:

    72expin tabular or in graphic form

  • Page 84 and 85:

    74facfactorial design D. where it i

  • Page 86 and 87:

    76foomised, IIa walking distance >

  • Page 88 and 89:

    78gamgamma error syn. type III erro

  • Page 90 and 91:

    80gengeneric name syn. internationa

  • Page 92 and 93:

    82googood clinical research practic

  • Page 94 and 95:

    84halhalf life (t 1/2) Time within

  • Page 96 and 97:

    86heaprofiles are designed for a wi

  • Page 98 and 99:

    88icdICD-9 code International Class

  • Page 100 and 101:

    90impthey choose to submit manuscri

  • Page 102 and 103:

    92infbe given to the person signing

  • Page 104 and 105:

    94insincluding at least one member

  • Page 106 and 107:

    96intinternal audit → see audit.i

  • Page 108 and 109:

    98invinvestigational drug syn. inve

  • Page 110 and 111:

    100isoquality intentions concerning

  • Page 112 and 113:

    102kapKaplan-Meier method syn. prod

  • Page 114 and 115:

    104lablabelling FDA: “all labels

  • Page 116 and 117:

    106lifprotection; since costs of la

  • Page 118 and 119:

    108identified amount produced in a

  • Page 120 and 121:

    110masmaster file → see Drug Mast

  • Page 122 and 123:

    112medto the FDA by phone as soon a

  • Page 124 and 125:

    114micby chemicals; → see also an

  • Page 126 and 127:

    116monmonitor’s visit log list sy

  • Page 128 and 129:

    11890 days), certifies the dossier

  • Page 130 and 131:

    120natnational drug list syn. natio

  • Page 132 and 133:

    122nofno-fault insurance syn.: no-f

  • Page 134 and 135:

    124null-hypothesis (Ho) Statistical

  • Page 136 and 137:

    126oncgests carcinogenic potential,

  • Page 138 and 139:

    128outintroduced in Japan (limit: J

  • Page 140 and 141:

    130pacpackage insert → see patien

  • Page 142 and 143:

    132patpatient log list → see subj

  • Page 144 and 145:

    134perthe market authorisation stat

  • Page 146 and 147:

    136phaing price (USA 42%, Western a

  • Page 148 and 149:

    138phatics and observational, non-e

  • Page 150 and 151:

    140pheunder non-trial conditions; t

  • Page 152 and 153:

    142pooing conventional procedures o

  • Page 154 and 155:

    144powoccurs; → see also Individu

  • Page 156 and 157:

    146preassessments are harmonised (e

  • Page 158 and 159:

    148proproduct licence application (

  • Page 160 and 161:

    150rejected and not the confidence

  • Page 162 and 163:

    152quatice; it operates upon all me

  • Page 164 and 165:

    154racracemate equimolar mixture of

  • Page 166 and 167:

    156rarall member states; after the

  • Page 168 and 169:

    158refreference pricing syn. fixed

  • Page 170 and 171:

    160reprepeated measures design D. w

  • Page 172 and 173:

    162ressize of one or more measurabl

  • Page 174 and 175:

    164rougastric emtying; dermal: lipi

  • Page 176 and 177:

    166safsafety alert Voluntary commun

  • Page 178 and 179:

    168serof true positive plus false n

  • Page 180 and 181:

    170sinsingle-dose toxicity syn. acu

  • Page 182 and 183:

    172sporive from a study or any orga

  • Page 184 and 185:

    174staical trials; SOP should descr

  • Page 186 and 187:

    176strstrength of medication; amoun

  • Page 188 and 189:

    178subsubject identification code l

  • Page 190 and 191:

    180methods of s.a. are the actuaria

  • Page 192 and 193:

    182three-way crossover design → s

  • Page 194 and 195:

    184toxthe FDA still requests 12 mon

  • Page 196 and 197:

    186treon how long the desired effec

  • Page 198 and 199:

    188vacvaccine A preparation that co

  • Page 200 and 201:

    190as ideal drug and is distributed

  • Page 202 and 203:

    192welestablished in previous ratin

  • Page 204 and 205:

    194whowhich can be used because dru

  • Page 206 and 207:

    196xenotransplantation Animal-to-hu

  • Page 208 and 209:

    198zero order kinetics → see kine

  • Page 210 and 211:

    200ADRADRACADROITADRRSADsAdSADTAEAE

  • Page 212 and 213:

    202ASCOASIASMFASRAS-ODNATCATCCAUCAV

  • Page 214 and 215:

    204CADD Computer Assisted Drug Desi

  • Page 216 and 217:

    206ChBCHDCHFCHMPCHOCHOPCICIBCIMCIOM

  • Page 218 and 219:

    208CRUCSCSACSDCSMCSRCSPCTCTACTCCTDC

  • Page 220 and 221:

    210DOBDoHD.P.DPMDRFDRLDSDDSMDSMBDSR

  • Page 222 and 223:

    212EPDEPhMRAEPLCePROEPSERERCPESCOPE

  • Page 224 and 225:

    214GHTFGIGILSPGITGLCGMGMCGM-CSFGMMG

  • Page 226 and 227:

    216ICD-9ICD-10ICDAICD-OICEICGEBICHI

  • Page 228 and 229:

    218LMWHLOCFLPILPOLRECLRTILUTILUTSLV

  • Page 230 and 231:

    220NANACDSNADNADANAFNAFTANAINAPMNAS

  • Page 232 and 233:

    222PCAPatient Controlled AnalgesiaP

  • Page 234 and 235:

    224RCGPRCCRCTR&DRDARDERDSREMRFPRHAR

  • Page 236 and 237:

    226StpSURSUSARSuspSVTTAATAPTBTBITCI

  • Page 238 and 239:

    228Selected bibliographyEuropean Co

  • Page 240 and 241:

    230WHOAdverse reaction dictionary.

  • Page 242 and 243:

    232Drug Research & Development1. Ph

  • Page 244 and 245:

    2344. The Practice of Medicinal Che

  • Page 246 and 247:

    2366. Practical Statistics for Medi

  • Page 248 and 249:

    2386. Medical Decision MakingSox H.

  • Page 250 and 251:

    240IFAPPInternational Federation of

  • Page 252 and 253:

    242http://www.infobiogen.fr/service

  • Page 254:

    244http://medicine.iupui.edu/flockh